Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease
- PMID: 20088619
- DOI: 10.2165/11310940-000000000-00000
Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease
Abstract
Levodopa is the most effective treatment for Parkinson's disease (PD) signs and symptoms, and patients invariably will require it during the course of the disease. It also provides benefits in activities of daily living, quality of life and life expectancy. However, after a few years of levodopa treatment the majority of patients will experience motor fluctuations and dyskinesia. Initial use of a dopamine receptor agonist may delay the emergence of motor fluctuations but at the cost of reduced symptomatic control compared with the use of levodopa in some cases. Adequate management of motor fluctuations and dyskinesia is essential to maintaining satisfactory quality of life at the advanced stage of disease. Various levodopa-based strategies are currently available that aim to control motor complications (wearing-off and dyskinesia) in PD and each approach has its own unique benefit and risk profile. Strategies such as dose fragmentation (smaller, more frequent dosing) or the use of orally administered, liquid levodopa formulations or melevodopa can reduce off-time intervals or facilitate absorption. More recently introduced, continuous delivery of dopaminergic medications may represent a more effective approach to treat motor complications in advanced PD and its effect can be perceived from improvement in clinical scales, as well as in health-related items. Indeed, continuous levodopa delivery by duodenal infusion may stabilize and significantly improve motor function as well as patients' quality of life. We propose a treatment algorithm that takes into account all currently available levodopa-based treatment strategies for motor complications in patients with PD.
Similar articles
-
Pulsatile or continuous dopaminomimetic strategies in Parkinson's disease.Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S120-2. doi: 10.1016/S1353-8020(11)70037-2. Parkinsonism Relat Disord. 2012. PMID: 22166407 Review.
-
Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.J Neural Transm (Vienna). 2018 Aug;125(8):1131-1135. doi: 10.1007/s00702-018-1906-0. Epub 2018 Jul 13. J Neural Transm (Vienna). 2018. PMID: 30006821 Review.
-
Medical Management and Prevention of Motor Complications in Parkinson's Disease.Neurotherapeutics. 2020 Oct;17(4):1339-1365. doi: 10.1007/s13311-020-00889-4. Neurotherapeutics. 2020. PMID: 32761324 Free PMC article. Review.
-
Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.Eur J Neurol. 2011 Mar;18 Suppl 1:3-10. doi: 10.1111/j.1468-1331.2010.03326.x. Eur J Neurol. 2011. PMID: 21255197 Review.
-
New dopaminergic therapies for PD motor complications.Neuropharmacology. 2022 Feb 15;204:108869. doi: 10.1016/j.neuropharm.2021.108869. Epub 2021 Nov 3. Neuropharmacology. 2022. PMID: 34742740 Review.
Cited by
-
Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics.NPJ Parkinsons Dis. 2018 Jan 24;4:4. doi: 10.1038/s41531-017-0040-2. eCollection 2018. NPJ Parkinsons Dis. 2018. PMID: 29387783 Free PMC article.
-
Effect of Levodopa-carbidopa Intestinal Gel on Non-motor Symptoms in Patients with Advanced Parkinson's Disease.Mov Disord Clin Pract. 2017 Nov-Dec;4(6):829-837. doi: 10.1002/mdc3.12526. Epub 2017 Sep 20. Mov Disord Clin Pract. 2017. PMID: 29242809 Free PMC article.
-
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson's Disease: DUOGLOBE Final 3-Year Results.J Parkinsons Dis. 2023;13(5):769-783. doi: 10.3233/JPD-225105. J Parkinsons Dis. 2023. PMID: 37302039 Free PMC article.
-
Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience.Ther Adv Neurol Disord. 2017 Mar;10(3):171-187. doi: 10.1177/1756285616681280. Epub 2016 Dec 1. Ther Adv Neurol Disord. 2017. PMID: 28344656 Free PMC article. Review.
-
Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.Mov Disord. 2021 Nov;36(11):2615-2623. doi: 10.1002/mds.28703. Epub 2021 Jul 8. Mov Disord. 2021. PMID: 34236101 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical